LR Health & Beauty SE announced its preliminary financial results for 2025. Total sales for full-year 2025 are now expected to reach $328 million, solidly in line with previously released guidance of $327 million to $333 million. The company expects EBITDA around $19 million for the full-year 2025, which is just below previously released guidance that advised EBITDA totals would be between $20 million and $23.75 million.
In tandem with its financial announcement, LR Health & Beauty also stated that consulting firm EY-Parthenon has completed a draft of an IDW S6 restructuring opinion with the goal of exploring the possibility of financial restructuring. As part of this restructuring, the company’s shareholder will inject an equity contribution of $11 million into the operating business and bondholders will receive a write-down of 55% of the nominal amount of bonds on a pro rata basis. The term of the bonds will be extended to the end of the year 2029. If the restructuring measures are not approved or cannot be implemented, bondholders were advised to expect an insolvency quota of around 6% in the case of an insolvency liquidation.
